632626-89-2

Upstream product

• 632626-88-1 3-(3-chloropropane-1-sulfonylamino)-5-nitro-benzoic acid methyl ester 
• 23218-93-1 3-amino-5-nitro-benzoic acid methyl ester 
• 618-84-8 3-amino-5-nitro-benzoic acid 

Downstream Products

• 632626-90-5 3-amino-5-(1,1-dioxo-1/⁶-isothiazolidin-2-yl)benzoic acid methyl ester 
• 632624-64-7 3-{2-[5-bromo-2-(2,4-difluorobenzyloxy)phenyl]-5-methyl-pyrrol-1-yl}-5-(1,1-dioxo-1/6-isothiazolidin-2-yl)benzoic acid 
• 632624-48-7 3-{2-[5-chloro-2-(2,3-difluorobenzyloxy)phenyl]-5-methyl-pyrrol-1-yl}-5-(1,1-dioxo-1/6-isothiazolidin-2-yl)benzoic acid 
• 632624-37-4 3-{2-[5-chloro-2-(2,6-difluorobenzyloxy)phenyl]-5-methyl-pyrrol-1-yl}-5-(1,1-dioxo-1/6-isothiazolidin-2-yl)benzoic acid 
• 632624-24-9 3-{2-[5-chloro-2-(4-bromo-2-fluorobenzyloxy)phenyl]-5-methyl-pyrrol-1-yl}-5-(1,1-dioxo-1/6-isothiazolidin-2-yl)benzoic acid 
• 632623-81-5 3-{2-[5-fluoro-2-(4-fluorobenzyloxy)phenyl]-5-methyl-pyrrol-1-yl}-5-(1,1-dioxo-1/6-isothiazolidin-2-yl)-benzoic acid 
• 632623-68-8 3-{2-[5-bromo-2-(4-fluorobenzyloxy)phenyl]-5-methyl-pyrrol-1-yl}-5-(1,1-dioxo-1/6-isothiazolidin-2-yl)benzoic acid 
• 632624-83-0 3-{2-[5-methyl-2-(4-fluorobenzyloxy)phenyl]-5-methyl-pyrrol-1-yl}-5-(1,1-dioxo-1/6-isothiazolidin-2-yl)benzoic acid 
• 632625-07-1 3-{2-[5-chloro-2-(benzyloxy)phenyl]-5-methyl-pyrrol-1-yl}-5-(2-oxo-pyrrolidin-1-yl)benzoic acid 

Relevant academic research and scientific papers

HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE

The present invention relates to novel hydroxyethylamine compounds of formula (I): (I) having Asp2 (-secretase, BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated-amyloid levels or-amyloid deposits, particularly Alzheimer's disease.

PYRROLE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES

Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein A, R1, R2a, R2b, Rx, R8, and R9 are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine, in particular their use in the treatment of prostaglandin mediated diseases such as pain, inflammatory, immunological, bone, neurodegenerative or renal disorder.